SWOG (formerly the Southwest Oncology Group) has chosen Sequenta's LymphoSIGHT platform for the measurement of minimal residual disease (MRD) in 180-patient mantle cell lymphoma clinical trial. The patients in the SWOG S1106 mantle cell ...
Tags: SWOG, Sequenta's LymphoSIGHT platform, minimal residual disease, MRD